135 results
8-K
EX-99.1
ACGN
Aceragen Inc
24 Sep 13
Other Events
12:00am
and effective by patients, the medical community, and third-party payors;
competition from other companies and their therapies;
changes in treatment … may obtain marketing approval from the FDA or other regulatory authorities will depend upon their acceptance by patients, the medical community
8-K
EX-99.1
ACGN
Aceragen Inc
5 Feb 14
Other Events
12:00am
products;
acceptance of the products as safe and effective by patients, the medical community, and third-party payors;
competition from other … , the medical community, and third-party payors as clinically useful, safe, and cost-effective. In addition, if products being developed by our competitors
8-K
EX-99.1
ACGN
Aceragen Inc
9 Feb 15
Entry into a Material Definitive Agreement
12:00am
of the products as safe and effective by patients, the medical community, and third-party payors;
competition from other companies and their therapies;
changes … regulatory authorities will depend upon their acceptance by patients, the medical community, and third-party payors as clinically useful, safe
8-K
mwaejhkv5ed9xh6r
12 Jan 15
Regulation FD Disclosure
12:00am
8-K
EX-99.2
r4anrewk p9n
1 May 20
Idera Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
8:10am
POS AM
m28ujapktvq9 nf0y
26 Nov 13
Prospectus update (post-effective amendment)
12:00am
8-K
5czjbt6e
15 Apr 04
Other events
12:00am
DEFA14A
ofrhqn jwum7eew2
1 May 20
Additional proxy soliciting materials
7:30am